
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4305521/publications.pdf Version: 2024-02-01



RILV M RIBEIRO

#	Article	IF	CITATIONS
1	Increased Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by Antiretroviral Therapy. Journal of Experimental Medicine, 2001, 194, 1277-1288.	8.5	329
2	Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus. Science Translational Medicine, 2010, 2, 30ra32.	12.4	327
3	Trypanosoma brucei Parasites Occupy and Functionally Adapt to the Adipose Tissue in Mice. Cell Host and Microbe, 2016, 19, 837-848.	11.0	288
4	Acute Loss of Intestinal CD4+ T Cells Is Not Predictive of Simian Immunodeficiency Virus Virulence. Journal of Immunology, 2007, 179, 3035-3046.	0.8	253
5	Real Time Bayesian Estimation of the Epidemic Potential of Emerging Infectious Diseases. PLoS ONE, 2008, 3, e2185.	2.5	245
6	HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nature Medicine, 2017, 23, 638-643.	30.7	233
7	Modeling the within-host dynamics of HIV infection. BMC Biology, 2013, 11, 96.	3.8	214
8	Production of resistant HIV mutants during antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7681-7686.	7.1	207
9	Estimation of the Initial Viral Growth Rate and Basic Reproductive Number during Acute HIV-1 Infection. Journal of Virology, 2010, 84, 6096-6102.	3.4	203
10	Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed. Hepatology, 2001, 34, 1012-1020.	7.3	201
11	Kinetics of Coinfection with Influenza A Virus and Streptococcus pneumoniae. PLoS Pathogens, 2013, 9, e1003238.	4.7	184
12	Nonlinear partial differential equations and applications: In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted?. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15572-15577.	7.1	177
13	Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology, 2003, 37, 1343-1350.	7.3	175
14	Modeling the mechanisms of acute hepatitis B virus infection. Journal of Theoretical Biology, 2007, 247, 23-35.	1.7	166
15	Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy. Journal of Theoretical Biology, 2007, 247, 371-381.	1.7	156
16	The frequency of resistant mutant virus before antiviral therapy. Aids, 1998, 12, 461-465.	2.2	151
17	CD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells. PLoS Pathogens, 2010, 6, e1000747.	4.7	146
18	Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate. PLoS Pathogens, 2012, 8, e1002881.	4.7	139

#	Article	IF	CITATIONS
19	Cutting Edge: Experimentally Induced Immune Activation in Natural Hosts of Simian Immunodeficiency Virus Induces Significant Increases in Viral Replication and CD4+ T Cell Depletion. Journal of Immunology, 2008, 181, 6687-6691.	0.8	137
20	The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood, 2009, 114, 2917-2925.	1.4	137
21	Dynamics of hepatitis B virus infection. Microbes and Infection, 2002, 4, 829-835.	1.9	119
22	Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology, 2007, 46, 16-21.	7.3	115
23	Modeling amantadine treatment of influenza A virus in vitro. Journal of Theoretical Biology, 2008, 254, 439-451.	1.7	114
24	In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	108
25	Kinetics of Virus-Specific CD8 + T Cells and the Control of Human Immunodeficiency Virus Infection. Journal of Virology, 2004, 78, 10096-10103.	3.4	105
26	Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 33-37.	2.1	103
27	The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5050-5055.	7.1	101
28	Simian Immunodeficiency Virus SIVagm Dynamics in African Green Monkeys. Journal of Virology, 2008, 82, 3713-3724.	3.4	101
29	Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Dynamics during HCV Treatment in HCV/HIV Coinfection. Journal of Infectious Diseases, 2003, 188, 1498-1507.	4.0	99
30	Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 Cells. Journal of Virology, 2007, 81, 750-760.	3.4	95
31	Inflammatory monocytes expressing tissue factor drive SIV and HIV coagulopathy. Science Translational Medicine, 2017, 9, .	12.4	94
32	Unequal Evolutionary Rates in the Human Immunodeficiency Virus Type 1 (HIV-1) Pandemic: the Evolutionary Rate of HIV-1 Slows Down When the Epidemic Rate Increases. Journal of Virology, 2007, 81, 10625-10635.	3.4	92
33	Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology, 2009, 49, 32-38.	7.3	86
34	Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. Journal of Clinical Investigation, 2014, 124, 2802-2806.	8.2	84
35	Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4+ T Cells and Is Reverted by CD8+ Cell Depletion. PLoS Pathogens, 2011, 7, e1002170.	4.7	82
36	Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology, 2006, 43, 943-953.	7.3	81

#	Article	IF	CITATIONS
37	Determining thymic output quantitatively: using models to interpret experimental Tâ€eell receptor excision circle (TREC) data. Immunological Reviews, 2007, 216, 21-34.	6.0	78
38	Current Estimates for HIV-1 Production Imply Rapid Viral Clearance in Lymphoid Tissues. PLoS Computational Biology, 2010, 6, e1000906.	3.2	75
39	Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood, 2012, 120, 1357-1366.	1.4	75
40	Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. PLoS Pathogens, 2012, 8, e1002880.	4.7	74
41	Use of Laser Capture Microdissection to Map Hepatitis C Virus–Positive Hepatocytes in Human Liver. Gastroenterology, 2013, 145, 1404-1413.e10.	1.3	74
42	Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transplantation, 2006, 12, 207-216.	2.4	73
43	Nail [^] ve and Memory Cell Turnover as Drivers of CCR5-to-CXCR4 Tropism Switch in Human Immunodeficiency Virus Type 1: Implications for Therapy. Journal of Virology, 2006, 80, 802-809.	3.4	73
44	Effect of 1918 PB1-F2 Expression on Influenza A Virus Infection Kinetics. PLoS Computational Biology, 2011, 7, e1001081.	3.2	67
45	Mechanisms Underlying CD4+ Treg Immune Regulation in the Adult: From Experiments to Models. Frontiers in Immunology, 2013, 4, 378.	4.8	63
46	Predicting the Impact of a Nonsterilizing Vaccine against Human Immunodeficiency Virus. Journal of Virology, 2004, 78, 11340-11351.	3.4	61
47	Antibody Responses during Hepatitis B Viral Infection. PLoS Computational Biology, 2014, 10, e1003730.	3.2	60
48	Th-1-Type Cytotoxic CD8 + T-Lymphocyte Responses to Simian Immunodeficiency Virus (SIV) Are a Consistent Feature of Natural SIV Infection in Sooty Mangabeys. Journal of Virology, 2006, 80, 2771-2783.	3.4	57
49	A Mathematical Model of Hepatitis C Virus Dynamics in Patients With High Baseline Viral Loads or Advanced Liver Disease. Gastroenterology, 2009, 136, 1402-1409.	1.3	56
50	Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology, 2003, 38, 509-517.	7.3	54
51	Neutrophil extracellular trap production contributes to pathogenesis in SIV-infected nonhuman primates. Journal of Clinical Investigation, 2018, 128, 5178-5183.	8.2	51
52	Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection. Journal of Immunology, 2002, 169, 4657-4666.	0.8	49
53	Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Mathematical Biosciences, 2004, 188, 47-62.	1.9	48
54	Viral Dynamics during Primary Simian Immunodeficiency Virus Infection: Effect of Time-Dependent Virus Infectivity. Journal of Virology, 2010, 84, 4302-4310.	3.4	48

#	Article	IF	CITATIONS
55	Modeling Viral and Drug Kinetics: Hepatitis C Virus Treatment with Pegylated Interferon Alfa-2b. Seminars in Liver Disease, 2003, 23, 013-018.	3.6	47
56	Modeling the Viral Dynamics of Influenza A Virus Infection. Critical Reviews in Immunology, 2010, 30, 291-298.	0.5	47
57	Mathematical modeling of viral kinetics:. Clinics in Liver Disease, 2003, 7, 163-178.	2.1	46
58	Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	46
59	Hepatitis B Virus Kinetics under Antiviral Therapy Sheds Light on Differences in Hepatitis B e Antigen Positive and Negative Infections. Journal of Infectious Diseases, 2010, 202, 1309-1318.	4.0	45
60	Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes. PLoS Computational Biology, 2014, 10, e1003934.	3.2	45
61	Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. PLoS Pathogens, 2017, 13, e1006478.	4.7	45
62	Virus phenotype switching and disease progression in HIVâ€4 infection. Proceedings of the Royal Society B: Biological Sciences, 1999, 266, 2523-2530.	2.6	44
63	Understanding the mechanisms and limitations of immune control of HIV. Immunological Reviews, 2007, 216, 164-175.	6.0	44
64	Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients. PLoS Pathogens, 2015, 11, e1004565.	4.7	44
65	Effect of B-Cell Depletion on Viral Replication and Clinical Outcome of Simian Immunodeficiency Virus Infection in a Natural Host. Journal of Virology, 2009, 83, 10347-10357.	3.4	43
66	Dynamics of T- and B-Lymphocyte Turnover in a Natural Host of Simian Immunodeficiency Virus. Journal of Virology, 2008, 82, 1084-1093.	3.4	42
67	Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. European Journal of Immunology, 2005, 35, 46-55.	2.9	40
68	Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. Journal of Hepatology, 2007, 47, 23-30.	3.7	39
69	Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection. Journal of the Royal Society Interface, 2016, 13, 20160130.	3.4	39
70	Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor. Bulletin of Mathematical Biology, 2012, 74, 1789-1817.	1.9	38
71	Antibiotic and Antiinflammatory Therapy Transiently Reduces Inflammation and Hypercoagulation in Acutely SIV-Infected Pigtailed Macaques. PLoS Pathogens, 2016, 12, e1005384.	4.7	38
72	Hepatitis B Virus Kinetics and Mathematical Modeling. Seminars in Liver Disease, 2004, 24, 11-16.	3.6	37

#	Article	IF	CITATIONS
73	Influence of Peak Viral Load on the Extent of CD4+ T-Cell Depletion in Simian HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 259-265.	2.1	37
74	Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. Journal of Hepatology, 2002, 37, 124-130.	3.7	36
75	Impact of Early Viral Kinetics on T-Cell Reactivity during Antiviral Therapy in Chronic Hepatitis B. Antiviral Therapy, 2007, 12, 705-718.	1.0	35
76	A stochastic model for primary HIV infection: optimal timing of therapy. Aids, 1999, 13, 351-357.	2.2	33
77	Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. Blood, 2009, 113, 4250-4261.	1.4	33
78	Experimental depletion of CD8+ cells in acutely SIVagm-Infected African Green Monkeys results in increased viral replication. Retrovirology, 2010, 7, 42.	2.0	33
79	Modeling HCV kinetics under therapy using PK and PD information. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 321-332.	3.3	32
80	Agent-based and phylogenetic analyses reveal how HIV-1 moves between risk groups: Injecting drug users sustain the heterosexual epidemic in Latvia. Epidemics, 2012, 4, 104-116.	3.0	32
81	Kinetics of Myeloid Dendritic Cell Trafficking and Activation: Impact on Progressive, Nonprogressive and Controlled SIV Infections. PLoS Pathogens, 2013, 9, e1003600.	4.7	32
82	Modeling Deuterated Glucose Labeling of T-lymphocytes. Bulletin of Mathematical Biology, 2002, 64, 385-405.	1.9	31
83	Hepatitis C Virus Genotype 1a NS5A Pretreatment Sequence Variation and Viral Kinetics in African American and White Patients. Journal of Infectious Diseases, 2005, 192, 1078-1087.	4.0	31
84	The race between infection and immunity: how do pathogens set the pace?. Trends in Immunology, 2009, 30, 61-66.	6.8	31
85	High-fat diet exacerbates SIV pathogenesis and accelerates disease progression. Journal of Clinical Investigation, 2019, 129, 5474-5488.	8.2	31
86	Estimating drug efficacy and viral dynamic parameters: HIV and HCV. Statistics in Medicine, 2008, 27, 4647-4657.	1.6	29
87	Mathematics in modern immunology. Interface Focus, 2016, 6, 20150093.	3.0	29
88	High-Potency Human Immunodeficiency Virus Vaccination Leads to Delayed and Reduced CD8 + T-Cell Expansion but Improved Virus Control. Journal of Virology, 2005, 79, 10059-10062.	3.4	28
89	Human systems immunology: Hypothesis-based modeling and unbiased data-driven approaches. Seminars in Immunology, 2013, 25, 193-200.	5.6	28
90	Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 103-113.	2.1	26

#	Article	IF	CITATIONS
91	The Contribution of the Thymus to the Recovery of Peripheral Naive T-Cell Numbers During Antiretroviral Treatment for HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 1-8.	2.1	26
92	Evolution of Drug-Resistant Viral Populations during Interruption of Antiretroviral Therapy. Journal of Virology, 2011, 85, 6403-6415.	3.4	26
93	The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans. Viruses, 2017, 9, 350.	3.3	25
94	Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination. Journal of Virology, 2004, 78, 5520-5522.	3.4	23
95	Probabilistic control of HIV latency and transactivation by the Tat gene circuit. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12453-12458.	7.1	23
96	Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology, 2009, 49, 1113-1121.	7.3	22
97	Immunovirological Analyses of Chronically Simian Immunodeficiency Virus SIVmnd-1- and SIVmnd-2-Infected Mandrills (Mandrillus sphinx). Journal of Virology, 2011, 85, 13077-13087.	3.4	22
98	Modelling deuterium labelling of lymphocytes with temporal and/or kinetic heterogeneity. Journal of the Royal Society Interface, 2012, 9, 2191-2200.	3.4	22
99	Introduction to modeling viral infections and immunity. Immunological Reviews, 2018, 285, 5-8.	6.0	22
100	A Hepatitis C Viral Kinetic Model that Allows for Time-Varying Drug Effectiveness. Antiviral Therapy, 2008, 13, 919-926.	1.0	22
101	Divisionâ€linked differentiation can account for CD8 ⁺ Tâ€cell phenotype <i>in vivo</i> . European Journal of Immunology, 2009, 39, 67-77.	2.9	21
102	Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study. Addiction, 2020, 115, 901-913.	3.3	21
103	The evolutionary rate dynamically tracks changes in HIV-1 epidemics: Application of a simple method for optimizing the evolutionary rate in phylogenetic trees with longitudinal data. Epidemics, 2009, 1, 230-239.	3.0	20
104	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2021, 8, ofab153.	0.9	20
105	Dynamics of CD4 + T cells in HIVâ€I infection. Immunology and Cell Biology, 2007, 85, 287-294.	2.3	19
106	Mathematical Modeling of HCV Infection and Treatment. Methods in Molecular Biology, 2009, 510, 439-453.	0.9	19
107	Modeling the Effects of Morphine on Simian Immunodeficiency Virus Dynamics. PLoS Computational Biology, 2016, 12, e1005127.	3.2	19
108	Modelling hepatitis C virus kinetics during treatment with pegylated interferon α-2b: errors in the estimation of viral kinetic parameters. Journal of Viral Hepatitis, 2008, 15, 357-362.	2.0	18

#	Article	IF	CITATIONS
109	Response network analysis of differential gene expression in human epithelial lung cells during avian influenza infections. BMC Bioinformatics, 2010, 11, 170.	2.6	18
110	Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). Aids, 2015, 29, 2419-2426.	2.2	18
111	Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. PLoS Pathogens, 2016, 12, e1005879.	4.7	18
112	Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antiviral Therapy, 2007, 12, 705-18.	1.0	18
113	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. Journal of Virology, 2016, 90, 152-166.	3.4	17
114	Dynamics of Simian Immunodeficiency Virus Two-Long-Terminal-Repeat Circles in the Presence and Absence of CD8 ⁺ Cells. Journal of Virology, 2018, 92, .	3.4	17
115	Single hepatocytes show persistence and transcriptional inactivity of hepatitis B. JCI Insight, 2020, 5, .	5.0	17
116	Molecular Markers Distinguishing T Cell Subtypes With TSDR Strand-Bias Methylation. Frontiers in Immunology, 2018, 9, 2540.	4.8	16
117	Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7139-E7148.	7.1	16
118	Towards Real Time Epidemiology: Data Assimilation, Modeling and Anomaly Detection of Health Surveillance Data Streams. Lecture Notes in Computer Science, 2007, , 79-90.	1.3	16
119	Estimating the Impact of Vaccination on Acute Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections. Journal of Virology, 2008, 82, 11589-11598.	3.4	15
120	A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antiviral Therapy, 2008, 13, 919-26.	1.0	15
121	The life span of ganglionic glia in murine sensory ganglia estimated by uptake of bromodeoxyuridine. Experimental Neurology, 2004, 186, 99-103.	4.1	14
122	Modeling the immune response to HIV infection. Current Opinion in Systems Biology, 2018, 12, 61-69.	2.6	14
123	Mutagenic effects of ribavirin in vivo. Journal of Hepatology, 2005, 43, 553-555.	3.7	13
124	Modelling the kinetics of hepatitis C virus RNA decline over 4Âweeks of treatment with pegylated interferon α-2b. Journal of Viral Hepatitis, 2008, 15, 379-382.	2.0	13
125	Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection. Frontiers in Microbiology, 2018, 9, 1326.	3.5	13
126	The dynamics of simian immunodeficiency virus after depletion of CD8+ cells. Immunological Reviews, 2018, 285, 26-37.	6.0	12

#	Article	IF	CITATIONS
127	Zika virus dynamics: Effects of inoculum dose, the innate immune response and viral interference. PLoS Computational Biology, 2021, 17, e1008564.	3.2	10
128	Serum lipids and prostate cancer. Journal of Clinical Laboratory Analysis, 2021, 35, e23705.	2.1	10
129	The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?. Clinica Chimica Acta, 2021, 520, 133-138.	1.1	10
130	Accelerated Immunodeficiency by Anti-CCR5 Treatment in HIV Infection. PLoS Computational Biology, 2009, 5, e1000467.	3.2	9
131	Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?. Anticancer Research, 2021, 41, 3067-3073.	1.1	7
132	13 Modelling the in vivo growth rate of HIV: implications for vaccination. Studies in Multidisciplinarity, 2005, , 231-246.	0.0	6
133	HIV influences clustering and intracellular replication of hepatitis C virus. Journal of Viral Hepatitis, 2021, 28, 334-344.	2.0	6
134	Comparison of Different Treatment Regimens for the Emergence of New Resistance Under Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 331-335.	2.1	5
135	Comparison of Different Treatment Regimens for the Emergence of New Resistance Under Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 331-335.	2.1	5
136	Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase. Journal of Hepatology, 2002, 37, 277-279.	3.7	5
137	The Analysis of HIV Dynamics Using Mathematical Models. , 2004, , 905-912.		5
138	Kinetics of Major Histocompatibility Class I Antigen Presentation in Acute Infection. Journal of Immunology, 2009, 182, 902-911.	0.8	5
139	Disentangling the lifespans of hepatitis C virusâ€infected cells and intracellular vRNA replicationâ€complexes during directâ€acting antiâ€viral therapy. Journal of Viral Hepatitis, 2020, 27, 261-269.	2.0	3
140	The impact of negative lymph nodes in the survival outcomes of pN+ patients following radical gastrectomy: the inverse lymph node ratio as a better score to study negative lymph nodes. Updates in Surgery, 2020, 72, 1031-1040.	2.0	3
141	Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations. In Vivo, 2021, 35, 3431-3439.	1.3	3
142	The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection. Virology, 2008, 381, 75-80.	2.4	2
143	The fate of CD4 + T cells under toleranceâ€inducing stimulation: a modeling perspective. Immunology and Cell Biology, 2013, 91, 652-660.	2.3	2
144	Special Issue "Mathematical Modeling of Viral Infections― Viruses, 2018, 10, 303.	3.3	2

#	Article	IF	CITATIONS
145	Noise Is Not Error: Detecting Parametric Heterogeneity Between Epidemiologic Time Series. Frontiers in Microbiology, 2018, 9, 1529.	3.5	1
146	Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART). PLoS ONE, 2018, 13, e0190908.	2.5	1
147	Consumption of Alcohol and Drugs in the School Population of Sao Tome and Principe. Acta Medica Portuguesa, 2020, 33, 237.	0.4	1
148	Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis. In Vivo, 2021, 35, 2207-2212.	1.3	1
149	MODELING THE IN VIVO DYNAMICS OF VIRAL INFECTIONS. , 2006, , .		1
150	A sheep in wolf's clothing. Hepatology, 2003, 38, 1588-1589.	7.3	0
151	Quantifying the activity of anti-HIV treatment in silico. Nature Medicine, 2012, 18, 355-356.	30.7	0
152	Parameter estimation and identifiability of a HIV-1 model. , 2013, , .		0
153	Modeling the Dynamics of CD4+ T Cells in HIV-1 Infection. , 2021, , 81-93.		0
154	Infective Endocarditis as the Cause of Death: A Populationbased Study in Portugal, from 2002 to 2018. Acta Medica Portuguesa, 2021, 34, .	0.4	0
155	Untangling the immune basis of disease susceptibility. ELife, 2020, 9, .	6.0	0